Botulinum toxin treatment in parkinsonism.

Journal of the neurological sciences 2024 Vol.456() p. 122810

Anandan C, Jankovic J

관련 도메인

Abstract

Botulinum toxin (BoNT) was approved by the United States Food and Drug Administration (FDA) in 1989 for facial movement disorders and strabismus, but since that time its indications have been expanding beyond neurologic and ophthalmologic disorders. This article is a narrative review of the therapeutic use of BoNT in tremors, dystonia, sialorrhea, bladder and other autonomic symptoms, levodopa-induced dyskinesia and other problems occuring in the setting of parkinsonism. Though FDA approval is lacking for some of these indications, expert experiences have shown that BoNT is often beneficial in this group of patients.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 2
해부 bladder scispacy 1
약물 BoNT → Botulinum toxin C0006055
Botulinum Toxins
scispacy 1
약물 FDA → Food and Drug Administration scispacy 1
질환 parkinsonism C0242422
Parkinsonian Disorders
scispacy 1
질환 strabismus C0038379
Strabismus
scispacy 1
질환 tremors C0040822
Tremor
scispacy 1
질환 dystonia C0013421
Dystonia
scispacy 1
질환 sialorrhea C0037036
Sialorrhea
scispacy 1
질환 dyskinesia C0013384
Dyskinetic syndrome
scispacy 1
기타 BoNT → Botulinum toxin scispacy 1
기타 patients scispacy 1

MeSH Terms

United States; Humans; Botulinum Toxins; Parkinson Disease; Parkinsonian Disorders; Tremor; Dystonic Disorders; Botulinum Toxins, Type A

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문